Accessibility Menu
Kuros Biosciences Ag logo

Kuros Biosciences Ag(OTC) CSBTF

Market Cap$1.01BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)+8,148%
5 Year+883%
1 Year-33%
1 Month+13%
$25.57
+6.23%
+1.50Today
Kuros Biosciences Ag last closing stock price
MetricPriceDate
Last closeUSD 25.572026-07-31
Kuros Biosciences Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 25.572026-07-20
1 month+12.54%USD 22.722026-06-25
3 month-8.68%USD 28.002026-04-24
Year to date-33.31%USD 38.342025-12-30
1 year-32.53%USD 37.902025-07-31
3 year+1,252.89%USD 1.892023-07-31
5 year+883.45%USD 2.602021-07-12
Since inception+8,148.26%USD 0.312016-03-29

Kuros Biosciences Ag Financials at a Glance

Market Cap

$1.01BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 205.11M

Net Income (TTM)

-CHF 2.08M

EPS (TTM)

$0.06

P/E Ratio

398.28

Dividend

$0.00

Beta (Volatility)

0.01 (Low)

Price

$25.57

Volume

45

Open

$25.57

Previous Close

$25.57

Daily Range

$25.57 - $25.57

52-Week Range

$22.72 - $42.81

Estimated Earnings Date

Aug 13, 2026

CSBTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kuros Biosciences Ag

Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, focused on developing innovative therapeutic solutions for tissue repair and bone regeneration. The company operates globally, with a diverse portfolio that includes medical devices and pharmaceuticals aimed at enhancing patient outcomes in various medical fields.

Products and Services
  • MagnetOs Granules and Putty for orthopedic and dental applications
  • KUR-111 and KUR-113 for advanced bone healing therapies
  • Neuroseal, a synthetic tissue sealant for surgical procedures
Growth Outlook
  • Recent quarterly revenue reached CHF 66 million, indicating strong market demand
  • Successful Phase 2b trials for KUR-111 and KUR-113 enhance future product pipeline
  • Strategic partnerships, including with Checkmate Pharmaceuticals, expand therapeutic reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of CHF 206 million reflects significant growth
  • Operating income margin improved to 6.4% in the latest quarter
  • Current ratio of 1.96 indicates strong liquidity position
Kuros Biosciences AG is positioned to capitalize on the growing demand for advanced medical solutions in tissue repair and bone regeneration. The company's innovative product offerings, combined with a robust pipeline of clinical trials, suggest a promising trajectory for future growth. Recent financial performance highlights, including a substantial increase in quarterly revenue and improved operating margins, further underscore the company's potential. With a strong liquidity position and strategic partnerships, Kuros Biosciences is well-equipped to navigate the competitive landscape of the biotechnology industry.
AI Generated • Jul 9, 2026

Industry

Biotechnology

Sector

Health Care

Employees

178

CEO

Christopher T. Fair

Website

kurosbio.com

Headquarters

Schlieren, ZH 8952, CH

CSBTF Financials

Key Financial Metrics (TTM)

Gross Margin

87.02%

Operating Margin

5.99%

Net Income Margin

1.26%

Return on Equity

2.28%

Return on Capital

10.73%

Return on Assets

1.53%

Earnings Yield

0.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.01BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

39.46M

Volume

45

Avg. Volume

314.127

Financials (TTM)

Gross Profit

CHF 174.77M

Operating Income

CHF 2.77M

EBITDA

CHF 9.64M

Operating Cash Flow

CHF 2.41M

Capital Expenditure

-CHF 3.21M

Free Cash Flow

-CHF 802.18K

Cash & ST Invst.

CHF 15.67M

Total Debt

CHF 1.39M

Kuros Biosciences Ag Performance Analysis

Kuros Biosciences Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 18,832,22424.6%
20232023-12-31CHF 37,349,28598.3%
20242024-12-31CHF 85,159,000128.0%
20252025-12-31CHF 146,058,00071.5%
Kuros Biosciences Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3053.9%
Q42024-12-3137.3%
Q22025-06-3045.2%
Q42025-12-314.1%
Kuros Biosciences Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF -0.4579.2%
20232023-12-31CHF -0.42-7.4%
20242024-12-31CHF -0.13-68.9%
20252025-12-31CHF 0.06N/A
Kuros Biosciences Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3097.6%
Q42024-12-31-1552.6%
Q22025-06-3046.3%
Q42025-12-31288.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CHF 66.07M

+219.2%

Gross Profit

CHF 56.40M

+223.7%

Gross Margin

85.36%

N/A

Market Cap

$1.01BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.67M

N/A

Employees

178

N/A

Net Income

CHF 3.65M

+142.1%

EBITDA

CHF 5.72M

+285.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CHF 15.67M

+10.3%

Total Debt

CHF 1.39M

-35.1%

Accounts Receivable

CHF 31.86M

+397.0%

Inventory

CHF 16.93M

+248.6%

Long Term Debt

CHF 737.00K

-52.9%

Short Term Debt

CHF 653.00K

+13.0%

Return on Assets

1.53%

N/A

Return on Invested Capital

10.51%

N/A

Free Cash Flow

CHF 914.82K

+139.2%

Operating Cash Flow

CHF 1.95M

+192.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNBIFSanBio Company Limited
$16.45+0.00%
PHMMFPharma Mar, S.A.
$86.09+0.00%
NPPNYNippon Shinyaku Co., Ltd.
$6.11+0.00%
MEOBFMesoblast Limited
$1.70+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About CSBTF

What is the current price of Kuros Biosciences Ag?

Kuros Biosciences Ag is trading at $25.57 per share.

What is the 52-week range for Kuros Biosciences Ag?

Over the past 52 weeks, Kuros Biosciences Ag has traded between $22.72 and $42.81.

How much debt does Kuros Biosciences Ag have?

As of the most recent reporting period, Kuros Biosciences Ag reported total debt of CHF 4.97M.

How much cash does Kuros Biosciences Ag have on hand?

Kuros Biosciences Ag reported CHF 19.77M in cash and cash equivalents in its most recent financial results.

What is Kuros Biosciences Ag’s dividend yield?

Kuros Biosciences Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services